Affordable Access

Publisher Website

Anesthetic drug development: Novel drugs and new approaches

Medknow Publications & Media Pvt Ltd
Publication Date
DOI: 10.4103/2152-7806.109179
  • Surgical Neurology International: Neurosurgical Developments On The Horizon
  • Design
  • Medicine
  • Pharmacology


The ideal sedative–hypnotic drug would be a rapidly titratable intravenous agent with a high therapeutic index and minimal side effects. The current efforts to develop such agents are primarily focused on modifying the structures of existing drugs to improve their pharmacodynamic and pharmacokinetic properties. Drugs currently under development using this rational design approach include analogues of midazolam, propofol, and etomidate, such as remimazolam, PF0713, and cyclopropyl methoxycarbonyl-etomidate (MOC-etomidate), respectively. An alternative approach involves the rapid screening of large libraries of molecules for activity in structural or phenotypic assays that approximate anesthetic and target receptor interactions. Such high-throughput screening offers the potential for identifying completely novel classes of drugs. Anesthetic drug development is experiencing a resurgence of interest because there are new demands on our clinical practice that can be met, at least in part, with better agents. The goal of this review is to provide the reader with a glimpse of the novel anesthetic drugs and new developmental approaches that lie on the horizon.

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times

More articles like this

Novel approaches to the development of anti-sepsis...

on Expert Opinion on Drug Discove... May 2014

New approaches in drug development and novel compo...

on IDrugs : the investigational d... June 1998

Use of newer anesthetic drugs.

on American Journal of Ophthalmol... August 1953

New drugs and novel agents.

on Current Opinion in Oncology December 1989
More articles like this..